Drug Reaction with Eosinophilia and Systemic Symptoms | NEJM
This review focuses on DRESS, a serious drug-induced T-cell–mediated condition with marked cutaneous and systemic effects.
Related Articles
Artificial intelligence improves mammography-based breast cancer risk prediction
Artificial intelligence (AI) is enabling us to delve deeply into the information inherent in a mammogram and identify novel features associated with high risk of…
Method of the Year 2024: spatial proteomics
Nature Methods – Approaches for profiling the spatial proteome in tissues are the basis of atlas-scale projects that are delivering on their promise for understanding…
Hyro AI raises $35M series B with Healthier Capital’s Amir Rubin
Hyro AI has brought in $35 million in an extension of its series B round, recently securing an investment from Healthier Capital, led by former…
Accuhealth, Signallamp rebrands as TelliHealth, appoints CEO
The chronic care management and remote patient monitoring company will be led by veteran healthcare executive Asif Ahmad.
The benefits of Ozempic and its kin may extend far beyond weight loss
Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight…
Redesign Health raises $175M after layoffs
Redesign’s new fund announcement follows a series of layoffs and strategic shifts for the company.
Serious Liver Injury Being Observed in Patients Without Cirrhosis
Monitor Liver Tests Often for Early Identification of Worsening Liver Function
Health insurer Centene forecasts upbeat 2025 profit amid cost pressures
U.S. health insurer Centene on Thursday projected 2025 profit above Wall Street expectations amid elevated costs in its government-backed plans and a public outcry over…
2024’s Women of Influence
Fierce Healthcare is proud to present our 2024 Women of Influence honorees—10 women doing groundbreaking, industry-leading and innovative work throughout healthcare.Each of the 10 women…
Autopsy of a Drug Withdrawal — The Case of Melphalan Flufenamide | NEJM
A December 2022 law introduced a new expedited withdrawal process for accelerated approvals. The first approval withdrawn with this pathway was that of melphalan flufenamide.